NCT03080051

Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain

Phase 0 Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Progressive Supranuclear Palsy or Alzheimer's Disease Compared to Healthy Volunteers

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Molecular NeuroImaging · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Accepted

Summary

The overall goal of this imaging trial is to evaluate \[18F\]MNI-952 (also known as \[18F\]UCB-K), a tau targeted PET radioligand.

Detailed description

The overall goal of this imaging trial is to evaluate \[18F\]MNI-952 (also known as \[18F\]UCB-K), a tau targeted PET radioligand. * To characterize \[18F\]MNI-952, a PET radioligand for imaging tau. * To visually and quantitatively assess brain uptake and pharmacokinetics of \[18F\]MNI-952, a PET imaging marker for tau pathology in individuals with Progressive Supranuclear Palsy (PSP) or Alzheimer's disease (AD) and compare with healthy volunteers (HV). * To evaluate the safety of a single injection of \[18F\]MNI-952. * To compare the distribution of tau (using \[18F\]MNI-952) and Aâ (using florbetapir) in AD subjects.

Conditions

• Progressive Supranuclear Palsy
• Alzheimer Disease
• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	[18F]MNI-952	Subjects will undergo PET imaging using \[18F\]MNI-952, a PET radioligand for imaging tau.
DRUG	[18F]Florbetapir	Subjects with Alzheimer's disease will receive a \[18F\]florbetapir scan to compare distribution of tau in the brain compared to that of \[18F\]MNI-952.

Timeline

• Start date: 2016-08-01
• Primary completion: 2017-03-06
• Completion: 2017-03-06
• First posted: 2017-03-15
• Last updated: 2017-10-06

Locations

1 site across 1 country: United States